Blog
Synthesis of Vepdegestrant (ARV-471): ChemAIRS® Route Design for the First Approved PROTAC
Synthesis of vepdegestrant (ARV-471): ChemAIRS® retrosynthetic analysis of the first FDA-approved PROTAC degrader for ESR1-mutated breast cancer.
Synthesis of Daraxonrasib (RMC-6236): ChemAIRS® Retrosynthetic Analysis Behind the FDA-Accepted RAS(ON) Inhibitor
Synthesis of daraxonrasib (RMC-6236): ChemAIRS® proposes discovery and process routes for the RAS(ON) inhibitor now under FDA review.
8 Mainstream Synthetic Accessibility Prediction Models: A Technical Comparison
We compared 8 mainstream synthetic accessibility scoring models against real synthesis step counts from 1.5M+ drug-like molecules - here is what we found, including the limitations of our own model.
Anticipating the Unexpected: How ChemAIRS Turns Impurity Surprises into a Thing of the Past
Unexpected impurities don't just slow you down — they're a business risk. See how ChemAIRS Impurity Prediction identifies process impurities before you run a single reaction, with real-world case studies from the synthesis of fostemsavir and vismodegib.